Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout Read more →
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds Read more →
Scancell to go public after winning reverse merger bid for troubled Neuphoria Read more →